ArticleOncotarget2018
Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 36 citations in OpenAlex.
- Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia.British journal of haematology · 2021Trial
- Review
- Minimal Residual Disease Detection: Implications for Clinical Diagnosis and Cancer Patient Treatment.MedComm · 2025Review
- Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.Bone marrow transplantation · 2025Review
- The Role of Nucleophosmin 1 (Life (Basel, Switzerland) · 2022Review
- Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia.Journal of hematology & oncology · 2021Review
- Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations.Blood advances · 2021Article
- Article
- Machine learning derived genomics driven prognostication for acute myeloid leukemia withLeukemia & lymphoma · 2020Article
- NPM1 Biology in Myeloid Neoplasia.Current hematologic malignancy reports · 2020Review
- The Impact ofTurkish journal of haematology : official journal of Turkish Society of Haematology · 2019Article
- Article
- The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients.Cancer cell international · 2019Article
- Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia-Real-World Context.Frontiers in oncology · 2019Article
Corrections and comments
- Erratum issued
Authors and funding
23 authors at 3 institutions in 1 country.
Funding
Abstract
Detection of measurable residual disease (MRD) by mutation specific techniques has prognostic relevance in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.